Risperidone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Risperidone

Examples of brand names: Risperdal [DE]

ATC code: N05AX08

Main use (for orientation): Schizophrenia

Documented research summary

Direct evidence of THC-related P-gp/brain-exposure change only in a mouse model. CBD pair experiments in animals and exploratory human lipidomics, not a human pharmacokinetic prediction. Cannabis use disorder treatment comparisons are context, not pharmacological interactions or UZEDY-specific.

Uncertainties and limitations

Subcutaneous UZEDY depot. General metabolism only; do not extrapolate depot release, switching or doses to oral studies.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

5 separately recorded findings. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0313

Type of result: Direct preclinical pharmacokinetic/pharmacodynamic pair assessment

Observation: Brain concentrations of risperidone/9-hydroxyrisperidone and behavioural effects reduced.

Mechanism: P-gp induction at the blood–brain barrier in a mouse model

Study type: Mouse pharmacokinetics/behaviour and P-gp knockout

Context studied: THC increased P-gp expression, with D2/5HT2A binding unchanged; clozapine comparison without the same effect.

Clinical interpretation: Direct preclinical transporter finding

Limitations and uncertainties: No human concentration evidence or clinical dose factor; do not automatically extrapolate to oral/long-acting injectable aripiprazole or paliperidone.

Original sources for this finding: The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions. [CA_P_28272498]

CBD – clinical signals

Finding ID: B0314

Type of result: Clinical combination with a lipidomics endpoint; no pharmacokinetic interaction evidence

Observation: Certain sphingolipid changes were reported to reverse in the pooled antipsychotic/CBD experiment; a separately established risperidone-specific effect cannot be inferred from the abstract.

Mechanism: Exploratory modulation of serum lipids during co-administration

Study type: Phase I lipidomics, 38 healthy volunteers across several arms

Context studied: Risperidone 3 mg/day as one of four antipsychotic arms; after 3 days, a further 6 days plus CBD 800 mg/day.

Clinical interpretation: Human biomarker, not long-term clinical benefit

Limitations and uncertainties: 38 is the overall cohort, not risperidone n. No established risperidone pharmacokinetic change or prevention of diabetes/obesity.

Original sources for this finding: Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol. [CA_P_38950483]

CBD – laboratory and animal studies

Finding ID: B0315

Type of result: Direct preclinical pair assessments

Observation: Model-dependent improvement in sociability and attenuation of locomotor/glucose changes.

Mechanism: Modulation of behaviour, motor and metabolic adverse effects

Study type: Valproate autism model and high-dose risperidone rat model

Context studied: Valproate model: CBD 100 mg/kg twice daily plus risperidone 0.1 mg/kg; other study: CBD 5 mg/kg, risperidone 10 mg/kg.

Clinical interpretation: No human-treatment recommendation

Limitations and uncertainties: High/different animal exposure; no patient synergy or established prevention of tardive dyskinesia.

Original sources for this finding: Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism. [BMED39604124]; Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone. [BMED36385633]

THC – laboratory and animal studies

Finding ID: B0316

Type of result: Direct preclinical investigation of the pair

Observation: Risperidone corrected acute THC-induced prepulse-inhibition impairment in a mouse model.

Mechanism: Dopaminergic modulation of prepulse inhibition

Study type: Mouse behavioural experiment

Context studied: THC 10 mg/kg and risperidone 0.1 mg/kg intraperitoneally.

Clinical interpretation: No recommendation for clinical self-treatment

Limitations and uncertainties: Not equivalent to loss of effect with chronic THC/P-gp modulation; protocols considered separately.

Original sources for this finding: Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. [BMED16820196]

Cannabis, non-standardised composition – clinical signals

Finding ID: B0317

Type of result: Treatment context; no direct evidence of a drug–drug interaction

Observation: Antipsychotic treatment investigated with sleep/relapse/hospital-stay endpoints.

Mechanism: Cannabis use disorder/psychosis treatment rather than an isolated pair effect

Study type: Cohorts and a small antipsychotic comparison

Context studied: Sleep comparison in urine-cannabis-positive people, n=50; Swedish registries; adolescent hospital-stay comparison; n=30 cannabis-psychosis RCT.

Clinical interpretation: Treatment context, not a pharmacokinetic interaction

Limitations and uncertainties: Confounding by use/adherence/diagnosis; long-acting-injection results not specifically UZEDY. No standard cannabis dose or evidence of safe co-use.

Original sources for this finding: Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive Urinalysis. [BMED30072895]; Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study. [BMED38534050]; Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study. [BMED41581246]; Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis. [BMED37861990]; Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial. [BMED24921450]

References and access status

[V2_LABEL_D0121] UZEDY (RISPERIDONE) INJECTION, SUSPENSION, EXTENDED RELEASE [TEVA PHARMACEUTICALS USA, INC.]

Original source / bibliographic reference

Authors: Teva Pharmaceuticals USA, Inc.

Year: 2025

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED39604124] Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism.

Original source / bibliographic reference

Authors: Costa MAD, Fernandes GZ, Maiochi E, Ebs MFP, Darós FDS, Bolan SJ, Costa RRN, de Rezende VL, da Silva GC, Bitencourt RM, Gonçalves CL.

Year: 2025

Source type: Publication; title and abstract reviewed

DOI: 10.1002/dneu.22955

PMID: 39604124

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[CA_P_38950483] Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol.

Original source / bibliographic reference

Authors: Jieu B, Sykorova EB, Rohleder C, Marcolini E, Hoffmann AE, Koethe D, Leweke FM, Couttas TA.

Year: 2024

Source type: Research Support, Non-U.S. Gov't; Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article

DOI: 10.1016/j.psychres.2024.116005

PMID: 38950483

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[BMED36385633] Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone.

Original source / bibliographic reference

Authors: Kajero JA, Seedat S, Ohaeri J, Akindele A, Aina O.

Year: 2022

Source type: Publication; title and abstract reviewed

DOI: 10.1038/s41598-022-24235-0

PMID: 36385633

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[CA_P_28272498] The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Original source / bibliographic reference

Authors: Brzozowska NI, de Tonnerre EJ, Li KM, Wang XS, Boucher AA, Callaghan PD, Kuligowski M, Wong A, Arnold JC.

Year: 2017

Source type: research-article; Journal Article

DOI: 10.1038/npp.2017.50

PMID: 28272498

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[BMED16820196] Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.

Original source / bibliographic reference

Authors: Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, Iwasaki K, Shoyama Y, Nishimura R, Fujiwara M.

Year: 2006

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.pbb.2006.05.018

PMID: 16820196

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED30072895] Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive Urinalysis.

Original source / bibliographic reference

Authors: Thomas-Brown PL, Martin JS, Sewell CA, Abel WD, Gossell-Williams MD.

Year: 2018

Source type: Publication; title and abstract reviewed

DOI: 10.3389/fphar.2018.00769

PMID: 30072895

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED38534050] Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study.

Original source / bibliographic reference

Authors: Denissoff A, Taipale H, Tiihonen J, Di Forti M, Mittendorfer-Rutz E, Tanskanen A, Mustonen A, Niemelä S.

Year: 2024

Source type: Publication; title and abstract reviewed

DOI: 10.1093/schbul/sbae034

PMID: 38534050

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED41581246] Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.

Original source / bibliographic reference

Authors: Mustonen A, Niemelä S, Denissoff A, Forti MD, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J, Taipale H.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.psychres.2026.116966

PMID: 41581246

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED37861990] Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.

Original source / bibliographic reference

Authors: Thurstone C, Loh R, Foreman K, Thurstone CA, Wolf C.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1089/cap.2023.0053

PMID: 37861990

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED24921450] Risperidone compared to haloperidol in cannabis-induced psychotic disorder: A double blind randomized controlled trial.

Original source / bibliographic reference

Authors: Berk S Brook F Nur M.

Year: 2000

Source type: Publication; title and abstract reviewed

DOI: 10.1080/13651500050518316

PMID: 24921450

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility